StockData
Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc. (CRBU) stock

CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3074% below fair value
$0.34−0.01 (-3.43%)

Close on Nov 17, 2026Market cap $36.53MP/E –Yield –

Caribou Biosciences cash

Cash and short-term investments held at the end of each period.

Caribou Biosciences's cash was $113.80M at Jun 30, 2026. For fiscal 2025 it was $142.80M, down 42.7% from the year before. The highest annual figure on record is $413.50M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$142.80M-42.7%
FY2024Dec 31, 2024$249.40M-33.0%
FY2023Dec 31, 2023$372.40M+17.5%
FY2022Dec 31, 2022$317.00M-23.3%
FY2021Dec 31, 2021$413.50M+2492.0%
FY2020Dec 31, 2020$15.95M-61.2%
FY2019Dec 31, 2019$41.07M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$113.80M-38.1%
Q1 FY2026Mar 31, 2026$118.60M-44.2%
Q4 FY2025Dec 31, 2025$142.80M-42.7%
Q3 FY2025Sep 30, 2025$159.20M-43.3%
Q2 FY2025Jun 30, 2025$183.90M-41.0%
Q1 FY2025Mar 31, 2025$212.50M-38.6%
Q4 FY2024Dec 31, 2024$249.40M-33.0%
Q3 FY2024Sep 30, 2024$281.00M-29.2%
Q2 FY2024Jun 30, 2024$311.80M+6.6%
Q1 FY2024Mar 31, 2024$345.90M+18.9%
Q4 FY2023Dec 31, 2023$372.40M+17.5%
Q3 FY2023Sep 30, 2023$396.70M+15.8%
Q2 FY2023Jun 30, 2023$292.50M-20.1%
Q1 FY2023Mar 31, 2023$291.00M-25.5%
Q4 FY2022Dec 31, 2022$317.00M-23.3%
Q3 FY2022Sep 30, 2022$342.60M-21.3%
Q2 FY2022Jun 30, 2022$366.10M+182.7%
Q1 FY2022Mar 31, 2022$390.80M+167.8%
Q4 FY2021Dec 31, 2021$413.50M+2492.0%
Q3 FY2021Sep 30, 2021$435.31M+1673.4%
Q2 FY2021Jun 30, 2021$129.52M+291.0%
Q1 FY2021Mar 31, 2021$145.92M+255.3%
Q4 FY2020Dec 31, 2020$15.95M–
Q3 FY2020Sep 30, 2020$24.55M–
Q2 FY2020Jun 30, 2020$33.13M–
Q4 FY2019Dec 31, 2019$41.07M–

More Caribou Biosciences figures

See a number that looks wrong?